Publicado 19/09/2019 12:02
- Comunicado -

Tresiba Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U

Further information

Media: Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com Investors: Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com Ann Sndermlle Rendbk +45 3075 2253 arnd@novonordisk.com

Contenido patrocinado